Watson Pharmaceuticals CEO Watson Smith is not the only pharma executive to tweet in the last few days about a fake article.
The CEO of Marathon Pharmaceuticals also posted a fake story, claiming that Marathon was a new drug discovery from Watson, that Marathon had been approved for treatment of depression.
The Marathon Pharma article was also false.
Marathon Pharma, Marathon Pharmaceutical, and Marathon Pharmaceutical are not in the same pharmaceutical industry.
Marathon Pharmaceutical is owned by Pfizer.
Marathon is an industry leader in the development of new antidepressant medications and is focused on developing an accelerated therapeutic response to treat major depressive disorder.
Marathon does not currently have a patent for its product, and it has received no FDA approvals to sell its product.
Marathon has filed for a patent on a new antidepressant medication, but that patent is currently pending.
Marathon’s product is already approved by the FDA and has been approved by a clinical trial in patients with major depressive disorders.
Marathon also does not have a clinical development license from the FDA.
Marathon was also the first drug discovery company to receive a patent application for its novel antidepressant treatment, Mirtazapine, in January of this year.
Marathon filed for its own patent application in May, which was granted.
Marathon recently announced that it would begin offering its product in the U.S. market.
Marathon announced the drug, which will treat depression in adults with major depression and bipolar disorder, in April.
Marathon previously had been granted a clinical-trial license to offer its antidepressant medication in Europe and Australia.
Marathon currently has more than a million patients in the United States and more than one million in Europe, including patients who have been treated for depression for years.
Marathon said that it expects the new treatment to be effective and will start offering it to patients in June.
Marathon expects to start offering Mirtaflex in the second half of 2020, although it is not clear when that will happen.
Marathon will also begin offering the antidepressant Mirtapine in Europe in the third quarter of 2020.
The company did not immediately respond to a request for comment.
Marathon declined to comment on the Marathon Pharma story.
The pharmaceutical company was also not available to comment.
HuffPost’s report also noted that Marathon Pharma had been under scrutiny from regulators in the past.
In 2014, Marathon was ordered to pay $7 million to settle a class action lawsuit from more than 30 individuals who claimed Marathon’s drug Mirtax caused them to lose their jobs.
Marathon later agreed to pay the money back to the plaintiffs.
The suit also alleged that Marathon and Marathon Pharma failed to properly train their employees.
In May 2016, Marathon and its parent company, Marathon Pharma Limited, were ordered to give back $5.3 million in payments from patients who received Mirtox, but they were allowed to keep their money.
The class action settlement was the largest class action payout in the history of the American Medical Association.
Marathon did not respond to requests for comment about the Marathon pharma story.
Watson Pharma has also faced criticism in the recent past.
The pharmacy giant has faced allegations of misconduct, including an investigation by the U!
News and World Report that found the company failed to report more than 1,000 allegations of workplace harassment and abuse by employees, and that some employees were denied access to the company’s data and financial information.
The World Health Organization has called on Watson to overhaul its policies and practices regarding harassment, including a report that the company admitted to hiring more than 10,000 women without their consent for jobs, and had paid out more than $8 million in settlements for employees who were subjected to inappropriate workplace conduct.
In a statement to HuffPost, a Watson spokesperson said that its team “stands behind all of our employees, all of their communities and the communities they serve.”
On the other side of the Twitter battle, Marathon’s own stock has surged significantly.
Marathon, which is based in London, is one of the world’s largest pharmaceutical companies, and its stock has grown by more than 50% since mid-2014.
In recent years, the stock has gone up by more more than 20% on the back of the company announcing a new batch of antidepressants in April, a new study showing that it has more patients who are treated for major depressive conditions, and a major new trial that suggests its antidepressant drug, Mirena, may have an effect on treating depression in those with bipolar disorder.
A spokeswoman for Marathon said in a statement that the stock price has been stable, and the company will continue to invest in its global health mission.
Marathon and the Pfizer subsidiary that owns the Marathon patent also announced plans to invest more than £300 million in new facilities in Britain.
Pfizer is a global pharmaceutical company that specializes in the use of novel medicines to treat illnesses including cancer, cardiovascular disease, diabetes, and Parkinson’s disease.